Fifteen common polymorphic variants at six loci (apolipoproteins AI, B, CIII and E, hepatic lipase and lipoprotein lipase) involved in plasma lipid transport have been studied in 210 northern Spanish men, of whom 98 had proven coronary artery disease. The other 112 men were clinically free from coronary artery disease and acted as controls. The genotypes were investigated for relationships with plasma lipid and lipoprotein levels, as well as for the presence of coronary artery disease. As expected, the mean levels of plasma triacylglycerols (triglycerides) and lipoprotein (a) and the number of smokers were significantly higher in the disease group, and high-density lipoprotein (HDL)-cholesterol was significantly lower. Surprisingly, plasma cholesterol and low-density lipoprotein cholesterol were not different between the two groups. With regard to the common mutations, plasma triacylglycerol levels were related to the HindIII variants of lipoprotein lipase (P 0.05), to the apolipoprotein CIII variant (C3175G in exon 4) and to the apolipoprotein AI XmnI polymorphisms (P 0.05 and P 0.02 respectively). The apolipoprotein E variants were related to plasma cholesterol (P 0.05), HDL-cholesterol (P 0.02), plasma triacylglycerols (P 0.05) and the triacylglycerol/HDL ratio (P 0.01). Only the three-codon insertion/deletion variants of the apolipoprotein B signal peptide region discriminated between the two groups with or without arterial disease (P l 0.02). The possible functional effects of these common mutations are discussed.
INTRODUCTION
Studies of concordance rates in monozygotic twins with premature coronary artery disease have emphasized the importance of family history, and demonstrate that genetic risk factors contribute to the susceptibility of individuals to the disease [1] . Several genetic loci involved in the regulation of blood pressure and lipid transport have already been implicated in the development of premature coronary atherosclerosis. For example, an insertion\deletion (I\D) polymorphism of the angiotensinogen-converting enzyme gene was found in some studies to be a risk factor for myocardial infarction [2] , although other studies have failed to confirm this relationship [3, 4] . Studies have also found that a bi-allelic polymorphism of the angiotensinogen gene (Met-235 Thr) relates to diastolic blood pressure and is associated with an increased univariate risk of coronary artery disease [5] . There are also many possible candidate genes for predisposition to coronary artery disease whose products are involved in lipoprotein catabolism and transport, such as the apolipoprotein E (apo E) variants [6] , variants at the apo AI\CIII\AIV gene cluster [7, 8] and lipoprotein (a) [Lp(a)] [9] . Other candidates are genes coding for lipoprotein receptors and for lipolytic enzymes such as lipoprotein lipase (LPL) and hepatic triacylglycerol lipase [10] .
Within Europe, there are marked differences in mortality rates from coronary heart disease. For males in Scotland this mortality rate is approx. 385 deaths per 100 000 per year ; for males in northern Spain (Catalonia) it is approx. 75 per 100 000 per year [11] . Although dietary habits and lifestyle differences between northern and southern Europe may account in part for these differences, there remains the possibility that genetic differences may predispose or protect one European population more than another. Moreover, gene loci that confer susceptibility, or protection, from coronary heart disease [12] may be quite different between northern and southern Europe, and there may be different geneenvironment interactions with regards to dietary composition, antioxidant intake, alcohol consumption, smoking habits, etc. For this reason, we have studied 15 polymorphic genetic variants at six loci involved in lipid transport that have been reported previously in the literature by at least three independent laboratories to relate to dyslipidaemia or coronary heart disease, to see if similar relationships are found in a northern Spanish population with or without coronary atherosclerosis.
METHODS

Subjects
A total of 210 male subjects (98 patients and 112 controls) were recruited serially for the study by the physicians and cardiac clinics of the Internal Medicine Department of the University Hospitals of Sant Joan (Reus, Spain). Consent was obtained from all subjects for participation in the study, and approval was obtained from the appropriate ethical committee. The 98 patients suffered from premature coronary artery disease (diagnosed before the age of 55 years), as defined by characteristic clinical features of myocardial infarction, typical changes on a 12-lead ECG and a rise in cardiac enzyme levels ; 71 had coronary angiograms, which were positive in all cases (a positive angiogram was defined as greater than 50 % stenosis in at least one vessel using the Sones and Judkins scoring technique [13] ). Blood samples were taken mainly at the time of the myocardial infarction, and the patients were not on lipid-lowering diets, lipid-lowering drugs or β-blockers at the time. Some subjects were on nitrates and aspirin, but these would not be expected to interfere with lipid levels in the short term. The subjects in the control group (n l 112) were age-and sex-matched to the patients, and were recruited serially from individuals attending a health screening clinic ; they had no personal or family history of coronary artery disease. They were recruited mainly from ' white-collar ' workers in Reus, Spain. Individuals with valvular heart disease, diabetes mellitus, familial hypercholesterolaemia, cancer, or renal, hepatic or any other chronic disease, or those on lipidlowering drugs, were not included in the study. Of the 210 subjects studied, 59 (14 patients and 45 controls) had never smoked, and other details of smoking habits (present and in the past) are given in Table 1 . Hypertension was defined as blood pressure of 160\ 90 mmHg. These blood pressure limits are taken from a Cochrane database from the Hypertension Group [14] . With regard to medication, patients were mainly on drugs such as nitrates (62 %), aspirin (90 %) and selective β1-blockers (32 %) at the time of sampling for lipid estimations. The risk factor profiles of both groups are presented in Table 1 .
Lipoprotein analyses
Plasma cholesterol, triacylglycerols (triglycerides) and lipoproteins were determined by enzymic methods using commercially available kits (from Boehringer Mannheim and Beckman Array Protein System, Beckman Instruments, Brea, CA, U.S.A.). Lp(a) was measured by an ELISA using polyclonal antibodies raised against purified Lp(a) (Mercodia Diagnostics, Uppsala, Sweden). High-Common genetic variants for coronary artery disease in Spain 
5h-ACAGAATTCGCCCCGGCCTGGTACAC-3h HhaI 5h-TAAGCTTGGCACGGCTGTCCAAGGA-3h density lipoprotein (HDL)-cholesterol was measured after precipitation of apo B-containing lipoproteins, and levels of low-density lipoprotein (LDL)-cholesterol were calculated using the Friedewald formula. Apolipoproteins were determined by immunonephelometry using monospecific polyclonal antisera from Greiner Biochemica (Flacht, Germany).
Genetic analyses
DNA was isolated from fresh or frozen whole blood cells anti-coagulated with EDTA, using a spin column method (Nucleon ; Scotlab Bioscience, Coatbridge, Lanarkshire, Scotland, U.K., or Quiagen, Hilden, Germany). It was redissolved in double-distilled water and stored at k20 mC.
Six loci were studied ; the variants analysed were : apo AI (PstI, MspI and XmnI) ; apo B (I\D polymorphism, EcoRI and XbaI), apo CIII (C3175G, exon 4), apo E (E2, E3 and E4), hepatic lipase (Thr-202 Thr ; silent mutation in the codon encoding residue 202) and LPL [HindIII in intron 8, Asp-9 Asn, Asn-291 Ser and Ser-447 ter (where ter denotes termination)].
Primers for the PCR were obtained from Genosys (Cambridge, U.K.). The primer sequences were derived from published data [15, 16] and our laboratory data.
Amplification of genomic DNA
Genomic DNA (0.2-0.5 µg) was amplified in 25 µl reaction mixtures containing 10 mmol\l Tris\HCl (pH 8.3), 50 mmol\l KCl, 0.001 % gelatin, 200 µmol\l each of dATP, dCTP, dGTP and dTTP, 2-3.5 mmol\l MgCl # , 0.5 µmol\l of each primer and 2.5 units of Taq DNA polymerase (Gibco BRL). The sequences of the primers that were used for mutation analysis are presented in Table 2 . The mixture was overlaid with mineral oil. All tubes, tips and buffers were autoclaved and the reaction mixture was UV-irradiated before addition of genomic DNA and Taq DNA polymerase, to minimize contamination. Blank controls containing no genomic DNA were run with each set of amplification reactions. The amplification cycle was performed on a Perkin-Elmer Cetus 480 thermal cycler, and entailed 5 min of denaturation at 96 mC followed by 35 cycles of 1 min at 94 mC, 1 min at 48-55 mC and 1 min at 72 mC. This was followed by 10 min of extension at 72 mC.
Digestion and electrophoresis
A 5 µl portion of digestion mixture containing the manufacturer's recommended restriction buffer and 5 units of restriction enzyme was added to the amplification product and incubated at 65 mC for 3 h with TaqI (Gibco BRL) for the Asp-9 Asn mutation of the LPL gene, or at 37 mC overnight with HindIII (Gibco BRL) for the intron 8 restriction fragment length polymorphism or with HinfI (Gibco BRL) for the Ser-447 ter mutation of the LPL gene. Subsequently, the samples were electrophoresed in TBE buffer (89 mmol Tris\ borate, 2 mmol\l EDTA, pH 8.3) in 2-3 % (w\v) agarose gels at 150 V for 1-1.5 h. DNA was visualized by staining the gels with ethidium bromide (0.5 µg\ml) and transillumination with UV light. The other lipoprotein genetic variants were analysed by methods published previously [17] .
Statistical analysis
Lipid parameters were compared between controls and affected subjects by calculation of the means and S.D.s and subsequent ANOVA (after logarithmic transformation for skewed parameters, e.g. plasma triacylglycerols). For data analysis, log Lp(a) values were used since the log values have an approximately normal distribution. The study was powered to allow detection with 90 % and an error rate of 5 % for the following concentrations : 18 mg\dl cholesterol, 57 mg\dl triacylglycerols, 4.5 mg\dl HDL-cholesterol, 9 mg\l apo AI, 11 mg\l apo B, 3.5 mg\l apo AII, 1.4 mg\l apo CIII, 17 mg\l Lp(a), 2.5 mg\l apo E and 0.7 mg\l apo CII.
We compared genotype distributions in the study groups using 2i3 contingency tables (controls and affected subjects versus genotype frequencies) or 2i2 contingency tables (controls and affected subjects versus genotype frequencies with amalgamation of heterozygotes and rare homozygotes). For bi-allelic traits, the study was powered to allow detection with 90 % and an error rate of 5 % for differences in allele frequency of 7.8 % where one allele has a 10 % frequency, of 12.3 % with a 35 % frequency, and of 12.9 % with a 50 % frequency. Frequencies were compared by Chi-squared tests (with continuity correction), or by Fisher's exact test where expected frequencies were less than 5.
Associations between lipid parameters and genotypes were analysed in two ways. First, each lipid parameter was divided into tertiles, and the frequency distributions of genotypes were compared for upper and lower tertiles as described above. Secondly, generalized linear modelling was performed for each lipid parameter against genotype, and initially included body mass index, weight, height, age, smoking and hypertension as co-variates. However, in every case these dropped out of the regression and so were not included in the final model. The analysis was performed by entering all relevant genes followed by backward regression with ' P to remove ' and ' P to enter ' of 0.05. Analyses were performed using SPSS version 6.0 (SPSS Inc., Chicago, IL, U.S.A.) and Datadesk version 6 (Data Description, Inc., Ithaca, NY, U.S.A.).
RESULTS
Clinical, biochemical and statistical characteristics of study groups Table 1 summarizes the clinical features and biochemical characteristics of the study groups. As expected, the mean levels of triacylglycerols, apo B and Lp(a) were higher and HDL-cholesterol levels were lower among patients in the arterial disease group than among controls. Total plasma cholesterol did not differ between the groups. Figure 1 presents a plot of log (probability\relative rank) values against relative rank. If the probabilities are evenly distributed, this should result in a horizontal straight line with values centred on zero. Probability values lower than expected (i.e. less than the relative rank) will yield negative values (i.e. points below the line). Some of the probability values less than zero are seen as being more extreme than expected by chance from the distribution of the majority of the values in the plot. We selected the lowest eight values for consideration in this paper. We did not use the Bonferroni correction, since it is known to be very conservative if the number of comparisons is large and assumes that the tests are all independent, which in the case of the lipid transport system they clearly are not. Several solutions have been proposed for this problem [18] , including graphical methods for examining the spread of probability values associated with multiple comparisons in a data set. Our graphical method is derived from that of Schweder and Spjotvoll [19] , which was validated and extended by Parker and Rothenberg [20] .
Apolipoprotein genotypes and lipid levels
Plasma triacylglycerol levels were related to the apo CIII variant (C3175G) (P l 0.05), to the apo AI XmnI polymorphism (P l 0.02) and to the apo E4 variant (P l 0.05), as shown in Table 3 . Triacylglycerol\HDL ratios also showed an association with the apo E polymorphisms (P l 0.02).
When the lipid distributions were analysed by tertiles, there were significant differences between the upper and Common genetic variants for coronary artery disease in Spain Values represent the percentages of the 210 subjects studied possessing the respective genotypes that fall in the upper or lower tertiles. The commonest genotype is in column 1 and the other two are pooled in column 2 (except for apo E).
The apo E column 1 shows the pooled numbers of subjects who possess either apo E2 or E3 genotypes in the combinations 3/2 or 3/3. Column 2 shows pooled numbers of subjects who possess an apo E allele. P values were calculated by logistic regression analysis : *P 0.05 ; **P 0.02 ; †P 0.01.
Subjects represented by genotypes (%)
Apo lower tertiles in the numbers of subjects who possessed genetic variants at the apo E locus (for tertiles of total cholesterol, P 0.05 ; HDL-cholesterol, P 0.02 ; plasma triacylglycerols, P 0.05 ; apo B, P 0.01 ; triacylglycerol\HDL ratio, P 0.01) ; at the apo CIII locus (for tertiles of plasma triacylglycerols, P 0.05 ; apo CIII, P 0.02 ; triacylglycerol\HDL ratio, P 0.05) ; and at the apo AI locus (for tertiles of plasma triacylglycerols, P 0.02 ; apo E variants, P 0.02) (Table 4) . A similar tertile analysis was performed in relation to LPL genotypes, which showed significant differences for the HindIII polymorphism and plasma triacylglycerols (P 0.05) ( Table 5) .
Genotypes in arterial disease
Case-control analyses of genotype distributions between the two groups with or without arterial disease showed significant differences only for the apo B I\D poly- Values represent the percentages of the 210 subjects studied possessing the respective genotypes that fall in the upper and lower tertiles. Column 1 includes common homozygotes ; column 2 includes heterozygotes and rare homozygotes. P values were calculated by logistic regression analysis : *P 0.05 ; **P 0.02. 
Subjects represented by LPL genotypes (%)
DISCUSSION
Spain has one of the lowest mortality rates for coronary artery disease in Europe [11] , yet many of the conventional risk factors show significant differences in patients with coronary artery disease when compared with healthy Spanish control subjects. The frequency of smokers was much higher in the arterial disease group, and plasma triacylglycerols and Lp(a) were also raised in this group, whereas HDL-cholesterol was lowered. It was of great interest that plasma cholesterol was not different between cases and controls, as it is in other European countries ; this may be due to local environmental factors such as regional diets and the low baseline levels of plasma cholesterol in this population. When LDL-cholesterol was examined, there was a trend for an increase in the disease group, but this did not reach statistical significance. Although this may be due to the small sample size, other conventional risk factors, such as smoking, HDL-cholesterol and Lp(a), did show up clearly in this size of study. Of the six lipid loci studied, only the apo B I\D polymorphism distinguished between cases and controls (P l 0.02). This polymorphism is a three-codon I\D in the apo B signal peptide, coding for either 27 or 24 amino acids in the peptide [21] . It does not affect apo B structure and appears to have moderate effects on fasting and postprandial lipids and on responsiveness to dietary lipids [22,22a] . There are divergent reports in the literature regarding its association with coronary artery disease. An early study in the U.S.A. [23] showed that the insertion allele was found at higher frequencies in a group of 84 survivors of myocardial infarction (P 0.01), but was not associated with variations in LDL-cholesterol levels. However, subsequent studies from Norway [24] and Japan [25] showed no differences in allele frequencies between cases and controls.
It is evident that none of the genetic polymorphisms in the present study could be used as markers for coronary artery disease in this Spanish population. From the scientific literature it is now apparent that many genetic polymorphisms may be involved in the heritability of coronary artery disease, and each may only contribute a small percentage to the overall genetic variance, making the practical use of genetic markers unlikely.
The genetic variants that we studied were much more strongly associated with the intermediate phenotypes of dyslipidaemia ; of these, the apolipoprotein variants appeared to show stronger relationships than the lipase variants. Thus, in confirmation of previous studies [26, 27] , individuals possessing the apo E4 genotype were found more frequently in the upper tertiles for plasma cholesterol, plasma triacylglycerols, apo B and plasma triacylglycerol\HDL ratios. The latter, when HDLcholesterol is low and plasma triacylglycerol levels are high ( 2.3 mmol\l), can predict an increase in coronary events, as described in the PROCAM [28, 29] , as well as other [13] , studies.
With regard to the apo CIII variant in exon 4 (where C3175 is transverted to G), individuals possessing the rare 3175G variant were found more frequently in the upper tertiles for plasma triacylglycerols and triacylglycerol\HDL ratios. Again this confirms many previous studies that have shown a relationship between this apo CIII variant and raised plasma triacylglycerols (see [30] for a review). The mechanism of this effect has not been elucidated, but may relate to the altered stability of the primary transcript, leading to altered translation of the apo CIII mRNA. Raised apo CIII levels are known to inhibit the clearance of very-low-density lipoprotein particles from plasma, probably by inhibiting the enzyme LPL [31] . It was of interest in this regard to observe in the present study a significant increase in the number of subjects possessing this variant in the upper tertile for plasma apo CIII.
None of the three common coding mutations of LPL (Asp-9 Asn, Asn-291 Ser and Ser-447 ter) showed differences between upper and lower tertiles for any of the plasma lipid levels studied. The LPL Ser-447 ter variant tended to be found more frequently in the lower tertile for plasma triacylglycerols, but this did not reach statistical significance. The strongest marker at the LPL locus was the intron 8 bi-allelic variant revealed by restriction digestion with HindIII. In confirmation of studies in northern Europe [32] , genotypes containing the H2 (rare) allele were found more frequently in subjects in the upper tertiles for plasma triacylglycerols and triacylglycerol\HDL ratios. Many other studies have shown different frequencies of the H2 allele in subjects with dyslipidaemia compared with controls, and in subjects with premature coronary artery disease [33, 34] . Studies have also shown a clear allele-dosage effect of the HindIII genotype on concentrations of HDL-cholesterol, and a significant association was found between these genotypes and the severity of coronary artery disease in men [35] . From our studies, it appears that the effect of the HindIII variants may not be attributed to linkage disequilibrium with the three coding mutations so far studied, suggesting that there may be other functional mutants in the vicinity of the HindIII restriction site that affect the clearance of plasma triacylglycerols. This may not necessarily involve the action of LPL, since it may be a marker for a nearby gene(s) that affects clearance of very-low-density lipoprotein.
The Catalonia region of Spain has a low mortality rate from coronary heart disease, as is found in other Mediterranean countries [11] . Plasma cholesterol levels did not discriminate between cases and controls. However, genetic variants reported to be associated with coronary artery disease risk are prevalent in this population, and are also associated with the expected risk profiles for plasma lipids. It would be of great interest to compare the frequencies of these genetic variants with those in northern Europe, and this is a topic of continuing work in our departments. Other factors, such as different dietary components (e.g. polyunsaturated fats, antioxidants, etc.) and other lifestyle differences, may play a modulating role for the low incidence of coronary artery disease in this population.
